BPC-157, TB-500 & MGF Blend — 10 mg / 7.5 mg / 1 mg (Lyophilized, RUO)

BPC-157, TB-500 & MGF Blend from Peptide Tech combines three widely studied research peptides in a single, lyophilized format for streamlined laboratory work. Each vial contains 10 mg BPC-157, 7.5 mg TB-500 (thymosin β₄), and 1 mg MGF (IGF-1 Ec E-peptide). Produced under GMP-aligned procedures with batch-level traceability and QR-linked COA access, this blend is intended strictly for laboratory research use only (RUO)—ideal for in-vitro, cell-based, and analytical workflows where identity, purity, and handling consistency are essential.

Specifications

Property	Details
Product Name	BPC-157, TB-500 & MGF Blend — 10 mg / 7.5 mg / 1 mg
Form	Lyophilized powder (freeze-dried)
Container	Sterile Type I glass vial (research-grade closure); QR batch ID
Appearance	White to off-white lyophilized cake/powder
Composition (per vial)	BPC-157 (10 mg); TB-500/thymosin β₄ (7.5 mg); MGF/IGF-1 Ec E-peptide (1 mg)
Purity / ID	Research-grade; identity & purity confirmed per lot (e.g., MS/HPLC); see COA
Intended Use	For laboratory research only (RUO); not for human or animal use, ingestion, diagnostic, therapeutic, or veterinary applications
Solubility (general)	Reconstitute with sterile water or compatible buffer; optimize pH/ionic strength per assay; filter (0.22 µm) if your protocol requires sterility
Storage	Store sealed, desiccated, and protected from light. Short-term: 2–8 °C. Long-term: ≤−20 °C. Avoid repeated freeze–thaw after reconstitution.

Component References & Identifiers

BPC-157 — CAS: 137525-51-0; Sequence: GEPPPGKPADDAGLV; Formula: C₆₂H₉₈N₁₆O₂₂; ~1419.5 g/mol; PubChem CID 9941957
TB-500 (thymosin β4) — CAS: 77591-33-4 (human Tβ4); 43 aa peptide; commonly referenced as timbetasin; PubChem CID 16132341 • structure/sequence resources: UniProt P62328
MGF (IGF-1 Ec E-peptide) — splice-variant E-peptide derived from IGF-1 (Ec isoform); identifiers vary by construct; CAS not universally assigned; reference protein: UniProt P05019 (IGF-1)

Molecular Structure

For visual reference, link to public structures/records

Key Features — Peptide Tech

Same-Day Shipping (Mon–Fri, in-stock)
GMP-Aligned lyophilization & packaging
USA Made with QR COA access
Third-Party USA Lab Testing — purity, quantity; endotoxin where applicable
Cold-Chain Shipping — Always (no paid upgrade)
Worldwide Shipping with compliant documentation
All Major Payments, text/email updates, and 2-Day FedEx/UPS standard

Potential Applications in Research

Examples below are strictly in-vitro, cell-based, or biochemical contexts; no health or therapeutic claims are made.

Endothelial tube-formation & migration assays (e.g., HUVEC) to profile angiogenesis-related signaling with BPC-157 or thymosin β4 under controlled conditions.
Actin dynamics / sequestration workflows (fluorescence-based polymerization, sedimentation) to examine thymosin β4 interactions with G-actin and effects on cytoskeletal remodeling.
Scratch/transwell cell-migration models in fibroblasts or endothelial lines to quantify motility changes in response to peptide exposure.
Myoblast proliferation/differentiation assays investigating IGF-1 Ec (MGF) E-peptide signaling versus mature IGF-1 using Erk/Akt readouts and myogenic markers.
Analytical method development (HPLC/LC-MS/MS) for multi-analyte blends: identity, assay, degradation profiling, and matrix effects.

Citations (MLA; supports the “Potential Applications” section)

Hsieh, Ming-Jer, et al. “Therapeutic Potential of Pro-Angiogenic BPC157 Is Associated with VEGFR2 Activation and Up-Regulation.” Journal of Molecular Medicine, vol. 95, no. 3, 2017, pp. 323–333. DOI: 10.1007/s00109-016-1488-y. Link.
Malinda, K. M., et al. “Thymosin Beta 4 Stimulates Directional Migration of Human Umbilical Vein Endothelial Cells.” FASEB Journal, vol. 11, no. 6, 1997, pp. 474–481. DOI: 10.1096/fasebj.11.6.9194528. Link.
Safer, D., et al. “Thymosin Beta 4 Binds Actin in an Extended Conformation and Contacts Both the Barbed and Pointed Ends.” Biochemistry, vol. 36, no. 19, 1997, pp. 5806–5816. DOI: 10.1021/bi970185v. Link.
Yang, Shou-Ying, and Geoffrey Goldspink. “Different Roles of the IGF-I Ec Peptide (MGF) and Mature IGF-I in Myoblast Proliferation and Differentiation.” FEBS Letters, vol. 522, 2002, pp. 156–160. DOI: 10.1016/S0014-5793(02)02991-1. Link.

Quality, Storage & Handling

Quality: Each lot is confirmed by MS/HPLC (see COA). Third-party testing performed in the U.S. where applicable.
Reconstitution: Bring vial to room temperature; add sterile solvent; swirl gently to dissolve; aliquot promptly. Avoid vigorous agitation/foaming.
After Reconstitution: Store aliquots at ≤−20 °C; avoid multiple freeze–thaw cycles.

Shipping & Fulfillment

Ships with validated cold-chain packaging. In-stock orders placed before the daily cutoff dispatch the same day. 2-Day FedEx/UPS is standard, with overnight options available. Automated text/email updates included; international service available where permitted.

Compliance & RUO Disclaimer

For laboratory research use only. Not a drug, food, or cosmetic. Not for human or animal use, ingestion, diagnostic, therapeutic, or veterinary applications. Purchasers must be qualified to handle RUO materials and comply with applicable laws and institutional policies.

FAQs

Are exact sequences provided?: Sequences for BPC-157 and thymosin β₄ are well established. MGF is an IGF-1 splice-variant E-peptide; specific construct details are listed on the lot COA.

What solvent should I start with?: Begin with sterile water or a neutral buffer. Adjust pH/ionic strength per your assay and confirm recovery; filter (0.22 µm) if your protocol requires sterility.
Can I get the COA?: Yes. Scan the vial’s QR code or contact support to access batch-specific documentation (identity, purity, and testing notes).